On 17 november, Wilbert Bannenberg, chair of the Pharmaceutical Accountability Foundation, presented at the regional Access to Medicines Dialogue of the EU Alliance. The dialogue is organized by the International Treatment Preparedness Coalition (ITPC) and hosted by the European Alliance for Responsible R&D and Affordable Medicines.
Wilbert was invited as speaker to tell about the use of competition law to act on an old drug becoming 500x more costly after registration as orphan drug. PAF filed an enforcement request on this CDCA case at the Dutch Competition Authority. Last summer, the ACM announced they fined pharmaceutic Leadiant for abuse of economical position with CDCA.
Find out what Wilbert presented about the CDCA case here.
Interested in the use of legal procedures to improve access to medicines? Join our webinar ‘The Power of Law‘ – on 22 November!